<DOC>
	<DOC>NCT00795353</DOC>
	<brief_summary>The study is a prospective, multi-centre, observational study designed to assess the long-term effectiveness and safety of alefacept in subjects with moderate to severe chronic plaque psoriasis.</brief_summary>
	<brief_title>Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description>Study includes a bio-marker sub-study to determine differences in responders vs. non-responders. Additional consent is required for the sub-study.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Subjects with moderate to severe chronic plaque psoriasis who receive a new prescription for alefacept Subjects with a contraindication to alefacept Subjects with a history of cancer except for adequately treated basal cell carcinoma (maximum of 2 lesions) Subjects with any active cancer, including skin cancer Subjects having a serious local infection (eg. cellulitis, abscess) or serious systemic infection (eg. pneumonia, septicemia, tuberculosis), within the 3 months prior to the first dose of alefacept. Subjects known to be infected with the AIDS virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>plaque psoriasis</keyword>
	<keyword>psoriasis</keyword>
	<keyword>alefacept</keyword>
	<keyword>Amevive</keyword>
</DOC>